K-group, Beta, Inc., A Wholly Owned Subsidiary Of Zentalis Pharmaceuticals, Inc

This study tested an experimental drug called ZN-c3 in 92 women with a rare and aggressive type of uterine cancer that had come back or not gone away. The goal was to see if the drug could shrink tumors and to check for side effects. Participants had already tried other treatment…

This early-stage study tested a new drug (ZN-c3) combined with standard chemotherapy (gemcitabine) in 31 people aged 12 and older whose osteosarcoma (a type of bone cancer) had returned or stopped responding to treatment. The main goals were to check safety and see if the combina…

This early-stage study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with solid tumors that had not responded to standard treatments. The main goals were to find a safe dose and to see if the drug could shrink tumors or slow their growth. The study is complete, and r…